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Abstract
Whole genome sequencing of viruses directly from clinical samples is integral for understanding the genetics of host-virus
interactions. Here, we report the use of sample sparing target enrichment (by hybridisation) for viral nucleic acid separation
and deep-sequencing of herpesvirus genomes directly from a range of clinical samples including saliva, blood, virus vesicles,
cerebrospinal fluid, and tumour cell lines. We demonstrate the effectiveness of the method by deep-sequencing 13 highly
cell-associated human herpesvirus genomes and generating full length genome alignments at high read depth. Moreover,
we show the specificity of the method enables the study of viral population structures and their diversity within a range of
clinical samples types.
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Introduction
Whole genome sequencing of viral genomes directly from
clinical samples is critically important for identifying genetic
variants which cause disease, including those that are under
positive selection pressure through interaction with the host [1].
Genetic variation defines virus population structures and is used
effectively in determining transmission chains [2]. In clinical
samples, viral genome copies per millilitre can number in the
billions yet the relative proportion of viral nucleic acid is minute in
comparison to host nucleic acid. Direct sequencing of mixed
human and viral nucleic acids yields representative proportions of
sequence reads that map to viral genomes [3], This represents a
significant issue when dealing with samples that contain low
proportions of viral nucleic acid and one that has limited such
studies from being carried out previously [4,5,6,7]. For this reason,
current methods for viral genome sequencing benefit significantly
from isolation of viral nucleic acid from host nucleic acid prior to
sequencing. The primary methods rely on the production of
microgram quantities of viral nucleic acid by either in vitro virus
culture or amplification of virus genomes by PCR [4,5,6,7].
However, both methods are known to alter virus population
structures either by replication advantages of subsets of viruses
during in vitro culture or through the introduction of nucleotide
mutations, gene deletions and genome rearrangements [8,9].
Moreover, the presence of PCR-inhibitory secondary structure
and the inability of many viral species to thrive in culture present
additional difficulties in generating sufficient quantities of viral
nucleic acid for whole genome sequencing. These factors all
impact on the accuracy of assembled genome sequences and the
interpretation of minority population structures.
Some of the hardest viral genomes to sequence are those of the
herpesviridae, a family of large highly cell associated (120–230 kilo
base pairs (kbp)) DNA viruses. The eight known human-infective
Herpesviruses are currently represented by 29 whole genome
sequences in GenBank. 18 of these represent Varicella-Zoster
Virus (VZV) strains, the causative agent chickenpox and shingles
while Epstein-Barr and Kaposi’s sarcoma-associated herpes viruses
(EBV and KSHV, respectively) are represented by only two strains
each. In all cases, these genomes were sequenced using viral
nucleic acid isolated from cultured material [7,10,11,12,13,
14,15,16,17,18]).
Target isolation by hybridisation and subsequent enrichment
has proven highly effective in exome sequencing studies [19],
enabling researchers to target and deep-sequence specific regions
within the human genome. This method uses overlapping 120-mer
biotinylated RNA baits, designed by tiling across targeted genomic
regions. Subsequent hybridisation of the RNA baits with sequence
library-prepared nucleic acid enables isolation and enrichment of
target material (using a minimal number of rounds of PCR) and
generating sufficient quantities for sequencing on second-genera-
tion platforms (Illumina, Roche, Abi). Moreover, while microgram
quantities of nucleic acid are still required for sequence library
preparation, the target genomes need only comprise a fraction of
the total nucleic acid [20].
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We describe here, the use of a solution-based target capture
methodology to separate and enrich for specific viral genomes
from low volume clinical samples comprising complex nucleic acid
mixtures (including excess human and bacterial nucleic acids). We
use a variety of approaches to determine the optimal method for
generating sufficient total nucleic acid for sequence library
preparation including whole genome amplification methods and
the use of carrier nucleic acid. The utility of the method is
demonstrated by directly sequencing 13 human herpesvirus
genomes from a range of clinical samples including blood, saliva,
vesicle fluid, cerebrospinal fluid and tumour cell lines.
Results and Discussion
Initially, total DNA was extracted from a range of VZV, EBV
and KSHV clinical and cultured samples (Table 1 and Table S1
online) and their viral loads determined. Due to the decreased
sensitivity of the qPCR assay (versus the PCR assay used to confirm
presence of viral DNA), no viral load data could be determined for
six VZV samples which were below the limit of detection. Five
samples underwent whole genome amplification (WGA) using the
high fidelity Phi29 DNA polymerase and random primers to
generate sufficient DNA for the library preparation step [21]. Viral
load assays, post-WGA, showed a large increase in viral nucleic acid
within the samples (Table S1). All remaining samples were prepared
without WGA, either directly (all culture samples and clinical
sample Vesicle I) or with the addition of carrier DNA (clinical
samples Blood I). Sequence library preparation, hybridisation and
subsequent enrichment were carried out on all samples using the
SureSelect Target Enrichment System (Agilent Technologies) [20]
and custom designed RNA baits. For comparison, two cultured
samples were amplified by overlapping long PCR and the products
mixed in equimolar ratios prior to sequence library preparation.
The viral load and human DNA content was determined for each
sample at the pre-hybridisation, post-hybridisation and post-
amplification stages and are expressed as a ratio (Table 1).
All samples were multiplexed (2-7 per lane) and sequenced using a
Genome Analyser IIx (Illumina, Inc) yielding between either
4.86107–7.26107 76bp paired-end reads per sample (clinical and
cultured samples) or 2.76107–3.36107 54 bp paired-end reads (long
PCR amplicons). Post-sequencing, read-pair quality control was
performed using QUASR (http://sourceforge.net/projects/quasr/),
and removing duplicate and low quality read-pairs. Consensus
genome sequences were produced by aligning read-pairs against a
reference genome using the Burrows-Wheeler Aligner [22] while
polymorphic loci (including SNPs) were reported using VarScan
[23]. The accuracy of SNPs identified in the assembled consensus
sequences for culture samples I and II and clinical samples Vesicle II
and CSF I was confirmed by either direct PCR and sanger
sequencing from the original material or prior reporting of the SNP
in peer-reviewed publications [24,25] (Table S2). In agreement with
previous studies, there was no evidence of error-induced substitutions
or indels in the consensus sequences of samples prepared using the
Phi29 DNA polymerase for WGA [26].
BLASTn [27] searches of unmapped read-pairs showed them to
of human or bacterial origin with minimal homology (,30%
identity) to the target enrichment probes, their presence attributed
to cross-hybridisation and insufficiently stringent post-hybridisa-
tion washes. For samples prepared using the SureSelect system,
34–99% of read-pairs mapped to the reference genomes enabling
the generation of full genome consensus sequences (Figure 1 and
Table S1). No correlation was observed between viral load and the
proportion of mapped reads. Several known short repetitive
sequences within the VZV, KSHV and EBV genomes could not
be accurately assembled with the BWA algorithm and are not
considered further. Genome coverage was lower for samples
prepared by long PCR than for target enriched sample. At
mapping depths of. 5x per nucleotide, genome coverage was 94–
98% for long PCR-prepared samples, compared with . 99% for
target enriched samples. At mapping depths of .100x per
nucleotide, genome coverage reduced to 88–92% for long PCR
samples and$ 94% for target enriched samples (Figure S1). These
differences are due to the presence of PCR-refractory regions
within the VZV genome which have no effect upon the target
separation and enrichment method. The specificity of the target
enrichment probe sets was confirmed by our ability to specifically
target and isolate either KSHV or EBV from a Primary Effusion
cell line lysate infected with both viruses using independent RNA
bait sets (Table 1). The successful enrichment of viral DNA in each
sample is shown by the significant increase in the ratio of
viral:human DNA post-hybridisation and is further evidenced by
the high proportion of sequence reads that map to the target
genome (Table 1).
Minority viral variants have been shown to be important in RNA
viruses and there is evidence that diverse population structures
among these viruses are strongly associated with viral evolution,
disease progression and treatment failure [28,29]. While large DNA
viruses are believed to exhibit minimal genetic variation, neither the
frequencies of minority variants, nor their biological importance, are
known. To examine this in VZV (one of the most stable of the
human herpesviruses), we defined polymorphic loci as positions at
which a minor allele was present at a frequency between 5–50%, the
total read depth exceeded 100 fold and a minimum of 5 independent
reads carry the minor allele (Figure 2). By plotting the frequencies of
each minority allele, relative to the consensus allele, we generated a
‘mutational spectrum’ for each sample showing that polymorphic
loci exist at between ,0.03–0.5% of positions in the genome
(Figure 3). The frequency of VZV genome positions with minority
bases was highest in two genomes (Culture III & IV) prepared by
long PCR and these also showed strong bias towards A to G and T to
C substitutions at minority variant positions, consistent with
sequence errors introduced by Taq–like polymerases [30]. In
contrast, no mutational pattern emerged in any samples prepared
by target enrichment confirming that no systemic bias was present.
For target enriched samples, those that underwent culture (Culture I
and II) had the lowest numbers of minority variant positions (, 40–
50) while the clinical samples were more variable. This likely reflects
a generalised tissue culture-related loss of diversity in culture samples
[8] while the relatively large proportion of polymorphic loci in CSF I
may be indicative of a more diverse population structure, the
significance of which is currently unknown.
These data demonstrate, for the first time, the suitability of
target capture technology for purifying very low quantities of viral
nucleic acid from complex DNA populations where the host
genome is in vast excess. This enables deep sequencing and
accurate alignment of full length viral genomes directly from
clinical samples using next generation technologies, making it far
superior to the culture and PCR–based methodologies. The
method is sample sparing (compared to traditional techniques),
compatible with WGA methods, automatable and applicable to a
range of other virus genome types, including RNA viruses. We
predict that the method is fully extendable to other pathogens
including bacteria and protozoa present in both clinical and
environmental samples. Moreover, the ability to recover multiple
viral genomes from a single clinical sample using pools of different
virus family capture probes offers the potential for next generation
multiplex genome sequence based diagnostic testing and studies of
host pathogen interactions.
Direct Sequencing of Viruses from Clinical Samples
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Figure 1. Coverage across sequenced genomes is highest using the target enrichment methods. Proportions of assembled genomes at
which read depth per base falls below 100 fold (lightest grey), 50 fold, 20 fold, 5 fold, 1 fold and 0 (indicated by increasing darkness).
doi:10.1371/journal.pone.0027805.g001
Figure 2. Total numbers of minority variant positions in all sequenced VZV samples. Each bar indicates the number of genome positions
at which multiple alleles are present (minor allele frequency 5–49.9%). Datasets are normalised (corrected for the total number of mapped reads per
sample) and showed no evidence that minority reads map to specific regions of the genome or that any bias between the proportions occurring in
coding and non–coding regions of the genomes is present. Viral genome copies, post-target enrichment could not be determined for some samples
(nd).
doi:10.1371/journal.pone.0027805.g002
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Materials and Methods
Ethics statement
Clinical specimens (diagnostic samples collected as part of
standard clinical procedures) were independently obtained from
patients with confirmed VZV infection and anonymised prior to
this study. Written consent was obtained in all cases. The use of
these specimens for research was approved by the East London
and City Health Authority Research Ethics Committee (P/96/
046: Molecular typing of cases of varicella zoster virus).
Repository of sequence read datasets
All VZV sequence datasets are available in the Sequence Read
Archive under the accession number SRA030888.1. All EBV and
KSHV datasets are available in the European Genome Archive
under the accession EGAS00001000141.
Sample preparation: VZV culture samples
VZV strains Culture I, II, III and IV were retrieved from the
Breuer Lab Biobank and cultured (2 passages) in Mewo cells
(MEM, 10% FCS, 1% Non-essential amino acids) at 34uC, 5%
CO2 until 70–80% cytopathic effect was observed. The
monolayer was scraped and centrifuged at 20 0g for 5 min and
DNA was extracted using a QiaAmp DNA mini kit (Qiagen)
according to manufacturer’s instructions.
Sample preparation: VZV diagnostic samples
Diagnostic samples from patients with confirmed VZV infection
were retrieved from the Breuer lab cryobank and included vesicle
fluid (Vesicle I, II, III and IV), Cerebro-spinal fluid (CSF I) and
saliva (Saliva I) and 2 samples adapted to culture (Culture I & II).
Total DNA was isolated from vesicle fluid, saliva and CSF using
a QiaAMP DNA mini kit according to manufacturer’s instruc-
tions. Peripheral blood mononuclear cells (PMBCs) were purified
from whole blood samples by centrifugation (1600 g, 15 minutes)
enabling separation of plasma (top layer) and PBMCs (middle
layer) from red blood cells (bottom layer) and total DNA extracted
using a QIAamp DNA Blood Mini Kit according to manufactur-
er’s instructions. Total DNA quantities were determined by
NanoDrop and those with a 260/280 ratio outside the range 1.9–
2.1 were further purified using the Zymoclean Genomic DNA
Clean & ConcentratorTM (Zymo Research Corp.).
Sample preparation: Primary effusion lymphoma cell
lines
PEL cell lines JSC-1 [31] and HBL6 [32] were cultured in
RPMI containing 10% FCS (Biosera) and pen/strep (100 units
ml21 penicillin and 100 mg ml21 streptomycin, Invitrogen). Lytic
reactivation of KSHV and EBV in PEL was induced by addition
of valproic acid (2.5 mg ml21) and 20 ml virus-containing
supernatant collected and 0.45 mm filtered after 72 hours. Viruses
were concentrated using 8% Poly(ethylene glycol) triphenylpho-
sphine (Sigma) and 0.15M NaCl. Samples were stored at 4uC for
12 hours before centrifuging (4uC, 2000 g for 10 min). The
supernatant was removed and discarded and the virus pellet re-
suspended into 200 ml PBS and DNA extracted using the QiaAmp
DNA Blood Mini Kit (Qiagen) according to manufacturer’s
instructions.
Whole genome amplification
5 clinical samples with very low total DNA quantities (with
variable viral loads) were amplified (10ng starting DNA) using
Genomiphi V2 (GE Healthcare) and purified using Zymoclean
Genomic DNA Clean & ConcentratorTM (Zymo Research Corp.),
both according to manufacturer’s instructions.
Figure 3. Mutational spectra of minority variants occurring within clinical samples. Each bar indicates the number of genome positions at
which specific allele combinations (see graphic) are present (minor allele frequency 1–10%). Datasets are normalised (corrected for the total number
of mapped reads per sample) and show a clear bias toward A to G and T to C substitutions in samples prepared by long PCR. No bias was observed in
samples prepared using target enrichment methods.
doi:10.1371/journal.pone.0027805.g003
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Viral load assays
The relative proportions of human and viral DNA within each
sample were determined by qPCR assays targeted at human
GTPase KRas (KRAS) and varicella-zoster virus ORF 29.
VZV DNA was measured by a real-time PCR assay used to
quantitatively detect viral DNA in clinical specimens. The PCR
targets a 78 bp region in ORF 29 of the VZV genome, a 78 bp
region in the EBV nuclear antigen leader protein and a 88 bp
region in KSHV ORF 73. For VZV, 1 ml of sample DNA was
diluted with 8 ml nuclease-free water and mixed with 12.5 ml of
Qiagen master mix (from Quantitect Multiplex PCR Kit
(Qiagen)), 0.94 ml (final concentration 0.94 mM) of the for-
ward primer 59 CACGTATTTTCAGTCCTCTTCAAGTG 39,
0.94 ml of the reverse primer 59 TTAGACGTGGAGTTGA-
CATCGTTT 39 and 0.1 ml of the FAM probe 59 FAM-
TACCGCCCGTGGAGCGCG -BHQ1 39 (final concentration
0.4 mM). For EBV, the EBNA-LP gene was targeted and samples
were prepared with the SensiMix dU kit (Bioline) using a 5 mM
MgCl2 concentration, forward and reverse primers at a 20 pmolar
final concentration (forward primer 59 GGCCAGAGG-
TAAGTGGACTTTAAT 39, reverse primer 59 GGGGACCCT-
GAGACGGG 39) and a probe at a 10 pmol final concentration
(59 FAM-CCCAACACTCCACCACACCCAGGC-BHQ1 39).
For KSHV, ORF 73 was targeted and samples were prepared
as for EBV using the following primers and probe (Forward
primer: 59 TTGCCACCCACGCAGTCT 39, Reverse primer: 59
GGACGCATAGGTGTTGAAGAGTCT 39, Probe: 59 FAM-
TCTTCTCAAAGGCCACCGCTTTCAAGTC-TAMRA 39) [33].
Quantitative PCRwas performed in a 96 well plate on an ABI 7300 or
a Masterplex thermocycler ep (Eppendorf) with an initial 15 minute
incubation at 95uC followed by 45 cycles at 95uC for 15 seconds and
60uC for 60 seconds. Ct values were compared to a standard curve
generated using a plasmid target to assign a copy number per
microliter. For human DNA, GTPase KRas was targeted using
forward (59 GCCTGCTGAAAATGACTGAATATAAAC 39) and
reverse (59 TGATTCTGAATTAGCTGTATCGTCAAG 39) prim-
ers at a 20pmolar final concentration. The relative proportion of
human and viral DNA copy numbers was subsequently calculated and
expressed as a ratio (Table 1).
SureSelect Target Enrichment: RNA bait design
Overlapping 120-mer RNA baits (generating a 2x coverage for
VZV and 5x coverage for EBV and KSHV) spanning the length
of the positive strand of the reference genomes were designed
using in house Perl scripts for VZV and Agilent eArray software
for KSHV and EBV. For VZV, a further 552 control baits were
designed against a 16 kbp region of the Salmo trutta trutta
mitochondrion (NC_010007). The specificity of all baits was
verified by BLASTn searches against the Human Genomic +
Transcript database. Bait libraries for EBV, KSHV and VZV
were uploaded to E-array and synthesised by Agilent Biotech-
nologies. All bait designs are available from the corresponding
author.
SureSelect Target Enrichment: Library preparation,
hybridisation and enrichment
DNA preparations of 3 mg, 500 ng and 250 ng (the latter
bulked with 2750 ng carrier DNA from MeWo cells) were sheared
for 6660 seconds using a Covaris E210 (duty cycle 10%, intensity
5 and 200 cycles per burst using frequency sweeping). End repair,
non-templated addition of 39-A, adaptor ligation, hybridisation,
enrichment PCR and all post- reaction cleanup steps were
performed according to the SureSelect Illumina Paired-End
Sequencing Library protocol (Version 1.0) observing all recom-
mended quality control steps.
Long PCR
Amplicons ranging from 1–6 kbp in size and spanning the
whole VZV genome were generated for culture strains 79A and
V110A. 30 overlapping primer pairs were designed against the
Dumas reference genome (NC_001348) as a template (Table S3).
All reactions were performed using the LongAmpH Taq PCR Kit
(NEB) and all PCR products size selected by gel purification with
the QIAquick Gel Extraction Kit (Qiagen) on 0.8% 1X TAE gels
stained with ethidium bromide. Cycling conditions were as follows:
Denaturation at 94uC for 3 min, followed by 45 cycles of
amplification (denaturation 94uC, 10 s; annealing 55uC, 40 s;
extension 65uC, 30 s – 5 m) and a final extension step at 65uC for
10 min. Gel purified amplicons were merged in equimolar ratios
prior to library preparation. Sequencing libraries were subse-
quently generated using the Nextera Tagmentation system
(Epicentre Biotechnologies). Here, 50 ng of each sample was
sheared and library prepped for paired end sequencing (2654 bp)
in a single reaction according to the manufacturer’s instructions.
Samples were tagged using the Nextera Barcode Kit and
multiplexed prior to flow cell preparation and cluster generation.
Illumina sequencing
Sample multiplexing (2 – 7 samples per lane on an 8 lane flow
cell) cluster generation and sequencing was conducted using an
Illumina Genome Analyzer IIx (Illumina Inc.) at UCL Genomics
(UCL, London, UK) or Wellcome Trust Sanger Institute
(Hinxton, UK). Base calling and sample demultiplexing were
performed using the standard Illumina pipeline (CASAVA 1.7)
producing paired FASTQ files for each sample.
Sequence data processing and alignment against
reference genomes
For each data set, all read-pairs were subject to quality control
using the QUASR pipeline (http://sourceforge.net/projects/
quasr/) to first trim the 39 end of reads (to ensure the median
Phred quality score of the last 15 bases exceeded 30) and
subsequently to remove read-pairs if either read had a median
Phred quality score below 30 or were less than 50 bp in length.
Duplicate read-pairs were also removed. All remaining read-pairs
were mapped to the reference genome using the Burrows-Wheeler
Aligner (maximum insert 50 bases, maximum distance between
paired ends 500) [34] generating SAM files containing all mapped
and unmapped reads. SAM files were subsequently processed
using SAMTools [35] to produce pileup files for consensus
sequence generation and SNP calling using VarScan v2.2.3 (--min-
coverage 3, --min-reads2 3, --p-value 5e-02) [23]. Unmapped
read-pairs were extracted from SAM files and BLASTn searches
used to determine the proportion mapping to the reference
genome [27]. Read-pairs with no significant hits were subsequent-
ly checked against the non-redundant database at NCBI to
determine their origin.
Supporting Information
Figure S1 Mean read depth across assembles genomes.
The mean read depth of each position in the assembled genome is
shown for (a) VZV culture samples, (b) VZV clinical samples
prepared without WGA, (c) VZV clinical samples prepared with
WGA, (d) VZV long PCR samples, (e) EBV and KSHV from
JSC1 cell lines and (f) EBV and KSHV rom HBL6 cell lines.
(TIF)
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Table S1 Deep sequencing of clinical samples prepared
using the SureSelect Target Enrichment System.
(DOCX)
Table S2 Confirmation of fixed SNPs identified in
assembled consensus sequences.
(DOCX)
Table S3 Primers used to generate overlapping ampli-
cons by long PCR for deep–sequencing of VZV.
(DOCX)
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